#1 Clinical Trials Search in Europe

Regn7508

REGN7508 is an experimental drug currently being studied in clinical trials for its potential to prevent blood clots in various medical situations. These trials are investigating the drug’s effectiveness, safety, and how it works in the body. The studies focus on different scenarios, including knee replacement surgery, catheter placement, and its use in combination with other medications. Researchers are also examining how the drug compares to existing treatments and its effects on healthy volunteers.

Table of Contents

What is REGN7508?

REGN7508 is an experimental drug currently being studied for its potential to prevent blood clots[1]. It belongs to a class of medications called monoclonal antibodies, which are laboratory-made proteins designed to target specific substances in the body[2]. In this case, REGN7508 targets a protein called Factor XI, which plays a role in blood clotting[4].

How Does REGN7508 Work?

REGN7508 works by targeting and inhibiting Factor XI, a protein involved in the blood clotting process[4]. By blocking this protein, REGN7508 may help prevent the formation of unwanted blood clots. This mechanism of action is different from traditional blood thinners, which often target other parts of the clotting process.

What Conditions Does REGN7508 Treat?

REGN7508 is being studied for its potential to prevent a condition called venous thromboembolism (VTE)[1]. VTE is a term that includes two related conditions:

  • Deep Vein Thrombosis (DVT): This occurs when a blood clot forms in a deep vein, usually in the leg[1].
  • Pulmonary Embolism (PE): This happens when a blood clot travels to the lungs, potentially blocking blood flow[1].

Specifically, REGN7508 is being investigated for preventing VTE in the following situations:

  • After knee replacement surgery[1]
  • In patients with a peripherally inserted central catheter (PICC), which is a type of intravenous line[2]

How is REGN7508 Administered?

REGN7508 is being tested in two main forms of administration:

  1. Intravenous (IV) injection: This involves giving the drug directly into a vein. In most trials, REGN7508 is administered as a single IV dose[1][2].
  2. Subcutaneous (SC) injection: This involves injecting the drug under the skin. Some trials are exploring this method of administration[4].

Current Clinical Trials

REGN7508 is currently being studied in several clinical trials:

  • ROXI-VTE II Trial: This study is testing REGN7508 for preventing blood clots after knee replacement surgery[1].
  • ROXI-CATH Trial: This trial is investigating REGN7508 for preventing blood clots in patients with a PICC line[2].
  • Gastrointestinal Blood Loss Study: This trial is comparing REGN7508 to other blood thinners to see if it causes less bleeding in the digestive system[3].
  • Phase 1 Safety Study: This early-stage trial is testing different doses of REGN7508 to evaluate its safety and how it works in the body[4].

Safety and Side Effects

As REGN7508 is still in the experimental stage, its full safety profile is not yet known. The ongoing clinical trials are designed to assess the drug’s safety and potential side effects. Some key points being studied include:

  • Bleeding risk: Researchers are monitoring for major bleeding and clinically relevant non-major bleeding[1][2].
  • Changes in blood clotting tests: The trials are measuring changes in tests like activated partial thromboplastin time (aPTT) and prothrombin time (PT), which indicate how quickly blood clots[1][2].
  • Immune system response: Researchers are checking if the body develops antibodies against REGN7508, which could affect its effectiveness or safety[1][2].

Future Prospects

If the ongoing clinical trials show positive results, REGN7508 could potentially offer a new option for preventing blood clots in various medical situations. Its unique mechanism of action, targeting Factor XI, might provide benefits over existing blood thinners, such as potentially causing less bleeding in the digestive system[3].

However, it’s important to remember that REGN7508 is still in the experimental stage. More research is needed to fully understand its effectiveness and safety before it can be considered for approval as a medication.

Aspect Details
Drug Name REGN7508
Drug Type Factor XI Monoclonal Antibody
Primary Purpose Prevention of Venous Thromboembolism (VTE)
Administration Single intravenous (IV) dose or subcutaneous (SC) injection
Trial Phases Phase 1 and Phase 2
Study Populations Knee replacement patients, PICC line patients, healthy volunteers
Key Outcomes Measured VTE incidence, bleeding events, drug concentrations, antibody formation
Comparators Enoxaparin, Rivaroxaban, Placebo
Safety Assessments Adverse events, bleeding incidents, changes in blood clotting tests

FAQ

  • What is REGN7508 and what is it being studied for? REGN7508 is an experimental drug being studied for its ability to prevent blood clots, particularly venous thromboembolism (VTE). It's being tested in various situations, such as after knee replacement surgery and in patients with catheters.
  • How is REGN7508 administered? REGN7508 is typically administered as a single intravenous (IV) dose. In some trials, it's also being tested as a subcutaneous (SC) injection.
  • What are the main outcomes being measured in these trials? The main outcomes include the incidence of blood clots, safety measures such as side effects and bleeding events, how much of the drug is in the blood over time, and whether the body produces antibodies against the drug.
  • How does REGN7508 compare to other blood thinners? Some trials are comparing REGN7508 to existing treatments like enoxaparin or rivaroxaban. One study is specifically looking at whether REGN7508 causes less intestinal bleeding than standard treatments when combined with aspirin.
  • Who can participate in these clinical trials? The trials involve various groups, including patients undergoing knee replacement surgery, those receiving a PICC line (a type of catheter), and healthy volunteers. Each trial has specific eligibility criteria.

Ongoing Clinical Trials on Regn7508

  • Comparison of REGN7508 versus apixaban and enoxaparin to prevent blood clots in adults after knee replacement surgery

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Hungary Latvia Lithuania Poland Romania

  • A study to evaluate the effectiveness of REGN7508 for preventing blood clots in adults with solid tumors undergoing cancer treatment.

    Not yet recruiting

    3 1
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Poland +2

  • A study to compare REGN7508 and acetylsalicylic acid for preventing blood clots in adults undergoing elective total knee replacement.

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Greece Italy

  • Study on REGN7508 for Preventing Blood Clots in Adults After Knee Replacement Surgery

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Bulgaria Hungary Latvia Lithuania Poland

Glossary

  • Venous Thromboembolism (VTE): A condition where blood clots form in the veins, usually in the legs or pelvis, and can travel to the lungs. It's a serious complication that can occur after surgery or in people with limited mobility.
  • Factor XI: A protein in the blood that plays a role in blood clotting. REGN7508 is designed to target and inhibit this protein to prevent excessive clotting.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to specific substances in the body. In this case, REGN7508 is a monoclonal antibody that targets Factor XI.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between the drug concentration and its effects.
  • Anti-drug Antibodies (ADA): Antibodies that the body may produce against a drug, which could potentially make the drug less effective or cause side effects.
  • Activated Partial Thromboplastin Time (aPTT): A blood test that measures how long it takes for blood to clot. It's used to monitor the effects of blood-thinning medications.
  • Prothrombin Time (PT): Another blood clotting test that measures how quickly blood clots form. It's also used to monitor blood-thinning medications.
  • Clinically Relevant Non-Major (CRNM) Bleeding: Bleeding that doesn't meet the criteria for major bleeding but is still considered significant in a clinical setting.
  • Peripherally Inserted Central Catheter (PICC): A type of intravenous catheter that is inserted into a vein in the arm and threaded to a large vein near the heart.

References